Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Método para obtener una vacuna destinada al tratamiento del melanoma

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOAR20150806001
Publicado:
02/03/2016
Caducidad:
02/03/2017
Resumen:
Un centro de investigación argentino especializado en impulsar la ciencia y tecnología ha desarrollado una tecnología que permite obtener una vacuna para el tratamiento del melanoma. Se trata de un método basado en la administración de líneas celulares heterólogas de melanoma con adyuvantes e inmunomoduladores (como BCG, GM-CSF o interferón alfa) y células dendríticas autólogas en pacientes con melanoma en etapas 2B, 2C o 3. El centro de investigación busca licenciatarios para adoptar y comercializar esta tecnología, que actualmente se está investigando en estudios clínicos de fase III.

Details

Tittle:
Method to obtain vaccine for melanoma treatment
Summary:
A research institution from Argentina, dedicated to the promotion of science and technology in this country and abroad, have developed an interesting technology to obtain vaccine for melanoma treatment. It consists of a method based on the administration of cell lines. This institution is currently looking for licensed partners to adopt and commercialize this technology, wich is already in phase III of clinical trials.
Description:
A research intitution from Argentina, dedicated to the promotion of science and technology in this country and abroad, has developed a technology consisting in an immunotherapy for treating melanomas.

The method is based on the administration of heterologous melanoma cell lines along with adjuvants and immunomodulators (such as BCG, GM-CSF or alfa interferon) and autologous dendritic cells, to patients with melanoma in stages 2B, 2C or 3.

Heterologous melanoma cell lines are irradiated with Gamma irradiation in order to obtain populations with apoptotic phenotype and populations with necrotic phenotype, incapable of proliferate.

The pharmaceutical formulation and process consists in:
1. Thawing and culturing melanoma cell lines.
2. Blending such cell lines.
3. Irradiating such cell lines.
4. Obtaining autologous dendritic cells from the patient.
5. Blending dendritic cells with irradiated melanoma cell lines and with excipientes and adjuvants.

Said injectable composition promotes the synthesis of specific T lymphocytes, which fight the tumour.

The research institution is looking for a partner able to adopt the technology (license) and capable to bring it to the market. The licensee will be responsible, also, of the registration with his/her national health authorities.
Advantages and Innovations:
The combination of different cell lines provides the presentation of a great variety of antigens, thus generating an excellent anti-tumour immune response.
Different cell lines mixture helps to stimulate maturity of autologous dendritic cells, fundamental for achieving an immune response.
The anti-tumour immune response generated by the vaccine is systemic.
The anti-tumour vaccine promotes the formation of tertiary lymphoid tissue. This new structure enhances interaction among the different types of cells involved in the immune response, thus increasing the kinetics of said response and generating a powerful anti-tumour protective effect.
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted,Patents granted
CommeR Statunts Regarding IPR Status:
Granted in: Argentina, Australia, Colombia, China, Europe (Denmark, France, Germany, Spain, Switzerland, United Kingdom, and The Netherlands), México, New Zealand, Russia, South Africa, USA and Japan.
Pending in: Brasil, Canada, India and South Korea.

Partner sought

Type and Role of Partner Sought:
Phase III clinical studies are being conducted in Argentina.
Therefore, this argentinian institution is currently looking for licensed partners to bring this technology to market and spread it into new regions.

Client

Type and Size of Client:
Industry >500
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001003 Citología, cancerología, oncología
06001015 Productos farmacéuticos / medicamentos
06001006 Vacunas humanas